Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines

Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma

(2012) Z. Li et al.   CLINICAL CANCER RESEARCH

The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

(2011) Ruixin Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells

(2011) Ruixin Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma

(2011) Joseph A. Knowles et al.   LARYNGOSCOPE

MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis

(2011) Y. Cheng et al.   MOLECULAR CANCER THERAPEUTICS

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

(2009) Brigette B. Y. Ma et al.   INVESTIGATIONAL NEW DRUGS

EBV Latent Membrane Protein 1 Effects on Plakoglobin, Cell Growth, and Migration

(2008) K. H.Y. Shair et al.   CANCER RESEARCH

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

(2008) N. T. Ihle et al.   CANCER RESEARCH

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions

(2008) Brigette B. Y. Ma et al.   CANCER SCIENCE

PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival

(2008) Chu-Chung Chou et al.   MEDICAL ONCOLOGY

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE